Positive results from BRIDGE Phase III open-label, switch-over trial evaluating pegunigalsidase alfa for treatment of Fabry Disease

This small study (n=22) reported an improvement in renal function as measured by the mean annualised eGFR slope , from ‑5.90 mL/min/1.73m2/year while on agalsidase alfa to -1.19 mL/min/1.73m2/year on pegunigalsidase alfa in all patients.

SPS commentary:

Pegunigalsidase alfa is an investigational enzyme replacement therapy. Currently in the UK, agalsidase alfa is licensed for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).


Biospace Inc.